Classification of the Crosslink Density Level of Para Rubber Thick Film of Medical Glove by Using Near-Infrared Spectral Data.

Classification of the crosslink density level of para rubber medical gloves by using near-infrared spectral data combined with machine learning is the first time reported in this paper. The spectra of medical glove samples with different crosslink densities acquired by an ultra-compact portable MicroNIR spectrometer were correlated with their crosslink density levels, which were referencely evaluated by the toluene swell index (TSI). The machine learning protocols used to classify the 3 groups of TSI were specified as less than 80% TSI, 80-88% TSI, and more than 88% TSI. The 80-88% TSI group was the group in which the compounded latex was suitable for medical glove production, which made the glove specification comply with the requirements of customers as indicated by the tensile test. The results show that when comparing the algorithms used for modeling, the linear discriminant analysis (LDA) developed by 2nd derivative spectra with 15 k-best selected wavelengths fairly accurately predicted the class but was most reliable among other algorithms, i.e., artificial neural networks (ANN), support vector machines (SVM), and k-nearest neighbors (kNN), due to higher prediction accuracy, precision, recall, and F1-score of the same value of 0.76 and no overfitting or underfitting prediction. This developed model can be implemented in the glove factory for screening purposes in the production line. However, deep learning modeling should be explored with a larger sample number required for better model performance.

Hypertension treatment in the Asia-Pacific: the role of and treatment strategies with nebivolol.

Hypertension is a common disease, and hypertensive patients are at increased risk of cardiovascular events. The prevalence and socioeconomic burden of hypertension in the Asia-Pacific region are predicted to increase in the coming decades. Effective blood pressure lowering reduces overall cardiovascular morbidity and mortality in patients, yet doubt has been raised regarding the use of (mainly older generation) ß-blockers as initial therapy in hypertension. Consequently, several international treatment guidelines do not recommend ß-blockers for the treatment of hypertension. However, in contrast to first-generation and second-generation ß-blockers, the third-generation, vasodilating ß-blocker nebivolol has a considerably better metabolic, haemodynamic and side effect profile. In addition to providing effective blood pressure control similar to other ß-blockers and drugs from other antihypertensive classes, nebivolol exerts a dual mechanism for increasing the bioavailability of the naturally occurring vasodilator nitric oxide. The clinical benefits and significance of enhancing nitric oxide levels in hypertensive patients have been shown in direct comparisons of nebivolol with other ß-blockers. While ß-blockers generally provide comparable blood pressure reductions, only nebivolol demonstrated enhanced vasodilation and blood flow by increasing the expression of endothelial nitric oxide synthase and therefore increasing nitric oxide release from the endothelium. In contrast to other ß-blockers, therefore, it has been suggested that nebivolol has beneficial effects in several hypertensive subgroups due to its vasodilating properties. Considering the existing data, it may be timely for treatment guidelines to recommend third-generation vasodilating ß-blockers as a first-line option for the pharmacotherapy of hypertension.

Effects of rosuvastatin on low-density lipoprotein cholesterol and plasma lipids in Asian patients with hypercholesterolemia.

AIMS: Rosuvastatin is more efficacious than other statins in lowering low-density lipoprotein cholesterol (LDL-C). Studies showing higher blood levels in Asians have resulted in concerns regarding increased adverse drug reactions. This study aimed to evaluate the efficacy and safety of rosuvastatin in hypercholesterolemic Asian patients. METHODS: This retrospective observational study was conducted on statin-naive patients and statin-switch patients. Patients were treated with rosuvastatin for > or =8 weeks. Primary outcomes were changes in LDL-C levels and proportions of patients achieving their goals (primary prevention, LDL-C < or =130 mg/dL; secondary prevention, LDL-C< or =100 mg/dL). RESULTS: Of 1007 hypercholesterolemic patients, 483 were statin-naive (LDL-C 161+/-40.8 mg/dL) and 524 were statin-switch patients (LDL-C 132.7+/-36.9 mg/dL). In statin-naive patients, rosuvastatin significantly reduced LDL-C, total cholesterol, and triglycerides by 39.9%, 28.8%, and 9.2%, respectively (p<0.001). Eighty-one percent of these patients achieved LDL-C goals. In the statin-switch cohort, LDL-C, total cholesterol, and triglycerides levels were significantly reduced by 24.5%, 16.6%, and 3.8%, respectively (p<0.001). Achievement of target LDL-C levels increased from 29% to 72.9%. There was no significant adverse drug reaction. CONCLUSION: Rosuvastatin was well tolerated and effective in lowering LDL-C in hypercholesterolemic Asian patients. Patients whose LDL-C levels were suboptimal on other statins improved their levels and more achieved LDL-C goals after switching to rosuvastatin.